KR20160147787A - 인간화 가변 림프구 수용체（ｖｌｒ） 및 이와 관련된 조성물 및 용도 - Google Patents

인간화 가변 림프구 수용체（ｖｌｒ） 및 이와 관련된 조성물 및 용도 Download PDF

Info

Publication number
KR20160147787A
KR20160147787A KR1020167030600A KR20167030600A KR20160147787A KR 20160147787 A KR20160147787 A KR 20160147787A KR 1020167030600 A KR1020167030600 A KR 1020167030600A KR 20167030600 A KR20167030600 A KR 20167030600A KR 20160147787 A KR20160147787 A KR 20160147787A
Authority
KR
South Korea
Prior art keywords
leu
xaa
amino acid
asn
ile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020167030600A
Other languages
English (en)
Korean (ko)
Inventor
브랜틀리 알. 헤린
맥스 데일 쿠퍼
루돌프 에르하르트
Original Assignee
에모리 유니버시티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에모리 유니버시티 filed Critical 에모리 유니버시티
Publication of KR20160147787A publication Critical patent/KR20160147787A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/461—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from fish
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020167030600A 2014-05-02 2015-04-30 인간화 가변 림프구 수용체（ｖｌｒ） 및 이와 관련된 조성물 및 용도 Ceased KR20160147787A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461987566P 2014-05-02 2014-05-02
US61/987,566 2014-05-02
PCT/US2015/028645 WO2015168469A1 (en) 2014-05-02 2015-04-30 Humanized variable lymphocyte receptors (vlr) and compositions and uses related thereto

Publications (1)

Publication Number Publication Date
KR20160147787A true KR20160147787A (ko) 2016-12-23

Family

ID=54359347

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167030600A Ceased KR20160147787A (ko) 2014-05-02 2015-04-30 인간화 가변 림프구 수용체（ｖｌｒ） 및 이와 관련된 조성물 및 용도

Country Status (8)

Country Link
US (3) US10167330B2 (enExample)
EP (1) EP3137496A4 (enExample)
JP (1) JP2017514522A (enExample)
KR (1) KR20160147787A (enExample)
CN (1) CN106459173A (enExample)
CA (1) CA2947429A1 (enExample)
IL (1) IL248327A0 (enExample)
WO (1) WO2015168469A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018212467A1 (ko) * 2017-05-18 2018-11-22 경상대학교산학협력단 소수성 테일 도메인이 제거된 먹장어 유래 vlrb 단백질에 칠성장어 유래 vlrb 단백질의 c 말단 서열이 연결된 융합 단백질 및 이의 용도

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160147787A (ko) 2014-05-02 2016-12-23 에모리 유니버시티 인간화 가변 림프구 수용체（ｖｌｒ） 및 이와 관련된 조성물 및 용도
SE1500434A1 (en) * 2015-10-29 2017-04-30 Theravac Pharmaceuticals Ab A novel fusion partner for highly efficient and safe vaccines
US11339225B2 (en) * 2016-05-12 2022-05-24 Asclepius (Suzhou) Technology Company Group, Co., Ltd. Bispecific antigen-binding construct and preparation method and use thereof
CN107365387B (zh) 2016-05-12 2022-03-15 阿思科力(苏州)生物科技有限公司 一种双特异性抗原结合构建体及其制备方法和应用
CN106543278B (zh) * 2016-12-06 2019-04-12 阿思科力(苏州)生物科技有限公司 融合蛋白Slit2D2(C386S)-HSA及其在治疗纤维化疾病中的应用
EP3573665A4 (en) * 2017-01-27 2020-11-11 Board Of Supervisors Of Louisiana State University BIFUNCTIONAL SMALL PEPTIDE FOR AUTOIMMUN DIABETES
BR112019019973A2 (pt) * 2017-03-24 2020-04-28 Orpheus Bioscience Inc pantlds para tratamento de transtornos autoimunes
MX2019012198A (es) * 2017-04-11 2020-01-21 Inhibrx Inc Constructos de polipéptidos multiespecíficos que tienen unión limitada a cd3 y métodos de utilización de los mismos.
US20190330366A1 (en) 2018-04-11 2019-10-31 Inhibrx, Inc. Multispecific polypeptide constructs having constrained cd3 binding and related methods and uses
EP3827019A1 (en) 2018-07-24 2021-06-02 Inhibrx, Inc. Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same
JP7611820B2 (ja) 2018-10-11 2025-01-10 インヒブルクス バイオサイエンシズ インコーポレイテッド Ｄｌｌ３シングルドメイン抗体およびその治療用組成物
WO2020132301A1 (en) * 2018-12-21 2020-06-25 Wisconsin Alumni Research Foundation Variable lymphocyte receptors that target the brain extracellular matrix and methods of use
WO2020167735A1 (en) 2019-02-11 2020-08-20 Wisconsin Alumni Research Foundation Variable lymphocyte receptors that target the blood brain barrier and methods of use
EP4377338A2 (en) 2021-07-27 2024-06-05 Novab, Inc. Engineered vlrb antibodies with immune effector functions
CN114891799B (zh) * 2022-05-20 2024-10-11 宁波大学 中华绒螯蟹可变淋巴受体vlr2基因及其编码的蛋白和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1118777A (ja) * 1997-07-09 1999-01-26 Asahi Chem Ind Co Ltd 新規スリット様ポリペプチド
US8039588B2 (en) * 2004-05-21 2011-10-18 The Uab Research Foundation Variable lymphocyte receptors
NZ574473A (en) 2006-08-02 2013-02-22 Uab Research Foundation Methods and compositions related to soluble monoclonal variable lymphocyte receptors of defined antigen specificity
WO2010065407A2 (en) 2008-12-01 2010-06-10 University Of Maryland Biotechnology Institute High affinity recombinant sea lamprey antibodies selected by a yeast surface display platform
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
CN104066751A (zh) 2011-11-22 2014-09-24 马里兰州大学(巴尔的摩) 对聚糖具有高亲和力和选择性的lambody及其用途
CN103033617B (zh) * 2012-11-30 2014-12-03 辽宁师范大学 基于可变淋巴细胞受体的肿瘤标志物检测试剂盒及其制备方法
TWI654206B (zh) 2013-03-16 2019-03-21 諾華公司 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
KR20160147787A (ko) 2014-05-02 2016-12-23 에모리 유니버시티 인간화 가변 림프구 수용체（ｖｌｒ） 및 이와 관련된 조성물 및 용도

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018212467A1 (ko) * 2017-05-18 2018-11-22 경상대학교산학협력단 소수성 테일 도메인이 제거된 먹장어 유래 vlrb 단백질에 칠성장어 유래 vlrb 단백질의 c 말단 서열이 연결된 융합 단백질 및 이의 용도

Also Published As

Publication number Publication date
WO2015168469A1 (en) 2015-11-05
IL248327A0 (en) 2016-11-30
US20170081385A1 (en) 2017-03-23
EP3137496A1 (en) 2017-03-08
US11384134B2 (en) 2022-07-12
CN106459173A (zh) 2017-02-22
US20200308247A1 (en) 2020-10-01
EP3137496A4 (en) 2017-10-11
JP2017514522A (ja) 2017-06-08
CA2947429A1 (en) 2015-11-05
US10167330B2 (en) 2019-01-01
US20190202887A1 (en) 2019-07-04

Similar Documents

Publication Publication Date Title
US11384134B2 (en) Recombinant vector and expression system comprising a nucleic acid encoding a variable lymphocyte receptor (VLR)
US11136369B2 (en) Expression of chimeric polypeptide with variable lymphocyte receptors on immune cells and uses for treating cancer
US20240084253A1 (en) Method of assessing activity of recombinant antigen receptors
JP7533898B2 (ja) 血中半減期の向上のための抗体Ｆｃ変異体
KR20230018488A (ko) 신종 코로나바이러스 스파이크 단백질 결합 분자 및 이의 응용
KR20180118783A (ko) 암에 대한 면역요법에서의 사용을 위하여 형질주입된 t 세포 및 t 세포 수용체
KR20140091031A (ko) 저밀도 지단백질-관련 단백질 6 (lrp6) - 반감기 연장제 구축물
US11447539B2 (en) PD-L1 binding fibronectin type III domains
JP2021508043A (ja) 新規抗原結合部分の特異性試験のためのユニバーサルレポーター細胞アッセイ
JP2021508246A (ja) 新規抗原結合部分の特異性試験のためのｃａｒ−ｔ細胞アッセイ
JP2021514648A (ja) 新規の標的抗原結合部分のための特異性アッセイ
WO2019192973A1 (en) Diagnostic assays to detect tumor antigens in cancer patients
CN111093696B (zh) 抗iii型纤连蛋白结构域的抗原结合区及其使用方法
CN114450410A (zh) 使用从头设计的共定位依赖蛋白开关的超特异性细胞靶向
JP2021518428A (ja) プログラム可能な免疫細胞受容体複合体システム
US20220411472A1 (en) Self-assembling circular tandem repeat proteins with increased stability
US12338286B2 (en) Aglycosylated antibody Fc region for treating cancer
WO2025129836A1 (en) An engineered cell
US12491255B2 (en) EPCAM binding fibronectin type III domains
WO2025059589A1 (en) Immune cell engaging molecules
US20230330239A1 (en) Epcam binding fibronectin type iii domains
CN115490773A (zh) 一种针对afp抗原的高亲和力t细胞受体

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20161101

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200429

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20210928

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20211214

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20210928

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I